Are Hair Cloning and Cultured Hair Follicle Transplantation Really “Almost Ready for Clinical Use”? — Dr. Moriwaki Honestly Assesses the Gap Between Research and Clinical Application2026.07.22
“Cultured hair follicle transplantation will be commercially available in a few years,” “With cloning technology, you can multiply your own hair infinitely” — dream-like news like this makes many patients wonder whether they should put off their current hair treatment and wait. However, at present, while there have been major advances at the basic research level, there is still a considerable distance before cultured hair follicle transplantation can be used as a routine clinical option. In this article, our supervising physician Dr. Moriwaki organizes the gap between the current research stage and clinical application, offering material to help you decide whether to wait or to act.
Key Points of This Article
・Cultured hair follicle transplantation is a regenerative medicine concept in which one’s own hair follicle cells are expanded in culture and returned to the scalp; if realized, it could break through the donor hair limitation.
・Even worldwide, large-scale human clinical trials remain limited, and reproducibility of density, hair quality, and graft survival remains a major challenge.
・Much of the “coming in a few years” reporting is based on preclinical data or small trials, and the road to regulatory approval and reimbursement is long.
・While you wait, AGA progresses and follicles miniaturize. Using currently available treatment to “protect” what you have preserves your future options.
・Maintaining the follicular environment with existing hair regenerative medicine such as stem cell conditioned media, oral, and topical drugs while the new technology matures is the realistic strategy.
What Is Cultured Hair Follicle Transplantation?
Today’s autologous hair transplantation takes donor follicles from the back of the head and grafts them directly to the frontal and vertex areas. The number of grafts is therefore capped by the donor supply and cannot cover extensive thinning. The concept designed to break this limit is a new form of regenerative medicine that takes harvested follicles, expands dermal papilla cells or follicular stem cells in vitro, and returns the expanded population to the scalp in the amount needed.
The Idea of “Multiplying” Follicles
Inside the follicle sits the dermal papilla (DP) cell — the “conductor” that signals surrounding epithelial cells to form a hair. In theory, if a few DP cells are harvested and expanded into thousands or tens of thousands in culture, many follicles could be reconstructed from a small donor pool. Animal studies have already reported hair follicle neogenesis, so the underlying possibility is not denied.
Why Clinical Translation Is Difficult
The problem is that DP cells cultured in vitro tend to lose their “hair-inducing capacity” as they are passaged. As passages accumulate, gene expression drifts, and even when the cells are returned to the scalp, follicles either fail to form or produce only thin, short, vellus-like hair — a phenomenon reported repeatedly. Research to overcome this through optimized culture conditions and three-dimensional spheroid techniques is advancing worldwide, but securing reproducible “stable density, hair quality, and direction” at a clinical level will take considerable time.
How to Read the “Coming Soon” Headlines
The Distance Between Research and Clinical Application
In medicine, “clinical use” requires basic research → preclinical → Phase I → Phase II → Phase III → application for approval → regulatory approval. Most cell-culture-based follicle reconstruction sits in the Phase I–II range, with subject numbers in the dozens. Only after large Phase III comparative trials demonstrate efficacy, safety, and reproducibility and regulatory approval is obtained can it be widely offered as a routine clinical option.
The Temperature Gap Between Press Releases and Peer-Reviewed Papers
Much “hair grew back” news comes from corporate press releases or preliminary conference presentations. It should be read calmly against basic yardsticks: has it been published in a peer-reviewed paper in a form that can be replicated, are conflicts of interest disclosed, and are subject numbers and follow-up periods adequate? For AGA treatment guidelines and safety evaluation principles, information from the Japanese Dermatological Association is also a useful reference.
The Pitfall Hidden in the “Wait” Strategy
Follicles Do Not Wait
AGA is a progressive disease. DHT-sensitive follicles miniaturize over years and eventually reach a state where they no longer produce hair. Once completely lost, follicles cannot be brought back even with current regenerative medicine. While you think, “I’ll hold off on treatment until it becomes available,” the very follicles that would form the base for a future transplant are declining.
The Importance of “Protecting” What You Have
Treatments with accumulating scientific evidence today include 5α-reductase inhibitors such as finasteride and dutasteride, minoxidil, scalp injection of stem cell conditioned media that acts on the follicular microenvironment, and microneedle RF such as Morpheus8. Combining these according to stage and slowing the shedding cycle is the greatest asset regardless of what new technology arrives in the future. Individual variation exists, but whether or not you secure this “defensive” period changes the breadth of your options years later.
How Cultured Hair Follicle Transplantation and Stem Cell Conditioned Media Are Positioned Differently
“The Cells Themselves” vs. “What the Cells Secrete”
The former is regenerative medicine in which cells that build follicles are expanded in vitro and transplanted; if realized, it may break through the donor limitation. The latter is treatment that uses the secretions — cytokines, growth factors, exosomes — released by stem cells during culture, and it aims to improve the microenvironment of existing follicles. The two work at different layers, “creating new follicles” versus “protecting and nurturing the follicles you have,” and cannot be compared on a simple superior-inferior axis.
A Complementary Positioning
Even if, in the future, cell-culture-based follicle reconstruction is realized, if the scalp environment in which the transplanted follicles must grow is inflamed and depleted, good results cannot be expected. Suppressing scalp microinflammation and preparing the vascular and growth-factor environment through conditioned media treatment will not lose its value in the new technology era. See our column list on hair regenerative medicine for how to combine existing and regenerative treatments.
Dr. Moriwaki’s Summary
Cultured hair follicle transplantation is a technology that will surely arrive one day, but we cannot promise it will become a routine clinical option “in a few years.” Watching research progress while using today’s treatments to protect follicles and prepare the scalp is the best strategy for keeping your future options open. How far to act today depends on individual progression, age, and follicular reserve, so we recommend building a plan while sharing your current status with a specialist. Please also understand that results vary by individual and definitive guarantees cannot be made.
Frequently Asked Questions
Q. In how many years will cultured hair follicle transplantation be available?
We cannot give a definite timeline. Most of the current technology is in small-scale clinical trial stages, and including large comparative trials, regulatory approval, and insurance coverage requires thinking on a scale of ten years or more. Please avoid postponing existing treatment based on excessive expectations.
Q. I am worried about hair loss progressing while I wait.
That concern is medically valid. AGA is progressive, and lost follicles cannot be brought back with current technology. Slowing the rate of follicle loss with current oral and topical therapies and stem cell conditioned media is the best way to preserve the base, regardless of what new technology may appear.
Q. Are stem cell conditioned media and cell-culture-based transplantation the same regenerative medicine?
Broadly, they share the same regenerative medicine framework, but their actions differ. Conditioned media aims to “improve the microenvironment of existing follicles,” while the latter aims to “rebuild new follicles themselves.” They target different layers, and it is natural to view them as complementary rather than competing.
Q. I heard there are clinics abroad offering cultured hair follicle transplantation.
There are cases where it is offered under clinical trial or private practice frameworks in some countries. However, regulation, quality control, and follow-up systems vary greatly by country, and handling of trouble is not the same as at a Japanese institution. Please avoid casual overseas treatment; careful information gathering and consultation with a domestic specialist are recommended.
Q. Will stem cell conditioned media become unnecessary once transplantation is available?
No. Conditioned media will continue to play the role of preparing the scalp environment in which transplanted follicles must grow. The two should be viewed as complementary rather than competing, and the value of existing treatment does not disappear even in a new technology era.
──────────────
【Supervisor】Shin Moriwaki, MD (Supervising Physician)
Member, Japan Society of Aesthetic Surgery (JSAS) / Member, American Academy of Aesthetic Medicine
ECFMG Certificate
──────────────
📍AVAN TOKYO Ginza Hair Regenerative Medicine
AVAN TOKYO Ginza Hair Regenerative Medicine
English / 中文 / Tiếng Việt supported
Inquiries welcome via DM / LINE / Website / Phone.